NCT01375751View on ClinicalTrials.gov

Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study

PHASE2CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

August 2, 2011

Primary Completion Date

May 16, 2012

Study Completion Date

May 16, 2012

Conditions
Hypercholesterolemia, Familial
Interventions
BIOLOGICAL

Evolocumab

Administered by subcutaneous injection

BIOLOGICAL

Placebo

d by subcutaneous injection

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01375751 - Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study | Biotech Hunter | Biotech Hunter